PL417544A1 - Sposób modyfikacji sekwencji polipeptydów oraz jej zastosowanie - Google Patents

Sposób modyfikacji sekwencji polipeptydów oraz jej zastosowanie

Info

Publication number
PL417544A1
PL417544A1 PL417544A PL41754416A PL417544A1 PL 417544 A1 PL417544 A1 PL 417544A1 PL 417544 A PL417544 A PL 417544A PL 41754416 A PL41754416 A PL 41754416A PL 417544 A1 PL417544 A1 PL 417544A1
Authority
PL
Poland
Prior art keywords
application
modification
polypeptide sequence
subject
modified
Prior art date
Application number
PL417544A
Other languages
English (en)
Other versions
PL238516B1 (pl
Inventor
Mateusz Krzyścik
Michał Łobocki
Aleksandra Sokołowska-Wędzina
Aleksandra Borek
Alicja Sochaj-Gregorczyk
Piotr Jakimowicz
Małgorzata Zakrzewska
Daniel Krowarsch
Jacek Otlewski
Original Assignee
Uniwersytet Wrocławski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Wrocławski filed Critical Uniwersytet Wrocławski
Priority to PL417544A priority Critical patent/PL238516B1/pl
Priority to PCT/IB2016/058083 priority patent/WO2017216620A1/en
Priority to EP16831758.4A priority patent/EP3468611A1/en
Publication of PL417544A1 publication Critical patent/PL417544A1/pl
Publication of PL238516B1 publication Critical patent/PL238516B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób modyfikacji polipeptydów, polegający na wprowadzeniu specyficznej sekwencji aminokwasowej (łącznika) do sekwencji aminokwasowej polipeptydu. Przedmiotem zgłoszenia jest też łącznik, który zawiera wysoce reaktywną resztę cysterny, którą można modyfikować powszechnie stosowanymi odczynnikami. Tak zmodyfikowane białko może służyć jako nośnik leku.
PL417544A 2016-06-13 2016-06-13 Sposób otrzymywania modyfikowanego polipeptydu PL238516B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL417544A PL238516B1 (pl) 2016-06-13 2016-06-13 Sposób otrzymywania modyfikowanego polipeptydu
PCT/IB2016/058083 WO2017216620A1 (en) 2016-06-13 2016-12-29 Human fibroblast growth factor 2 (fgf2) - cytotoxic drug conjugates for targeted therapy of fgfr-related cancers
EP16831758.4A EP3468611A1 (en) 2016-06-13 2016-12-29 Human fibroblast growth factor 2 (fgf2) - cytotoxic drug conjugates for targeted therapy of fgfr-related cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL417544A PL238516B1 (pl) 2016-06-13 2016-06-13 Sposób otrzymywania modyfikowanego polipeptydu

Publications (2)

Publication Number Publication Date
PL417544A1 true PL417544A1 (pl) 2017-12-18
PL238516B1 PL238516B1 (pl) 2021-08-30

Family

ID=57915022

Family Applications (1)

Application Number Title Priority Date Filing Date
PL417544A PL238516B1 (pl) 2016-06-13 2016-06-13 Sposób otrzymywania modyfikowanego polipeptydu

Country Status (3)

Country Link
EP (1) EP3468611A1 (pl)
PL (1) PL238516B1 (pl)
WO (1) WO2017216620A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020080656A1 (ko) * 2018-10-15 2020-04-23 국립암센터 Fgf2 또는 api5 유래 펩타이드 및 그의 용도
KR102241134B1 (ko) * 2019-08-08 2021-04-16 국립암센터 Fgf2 또는 api5 유래 펩타이드를 발현하는 항암 바이러스 및 이의 용도
US12403179B2 (en) 2021-02-18 2025-09-02 The Board Of Trustees Of The University Of Arkansas Release of growth factors at wound healing stages
CN116650679A (zh) * 2023-04-14 2023-08-29 河北医科大学第四医院 一种靶向fgfr1的影像探针及其应用
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
CN121891539A (zh) * 2026-02-06 2026-04-21 深圳大学 一种靶向iCAFs亚群的FGF2抑制剂组合物及其在膀胱癌防治中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
WO1992004918A1 (en) * 1990-09-19 1992-04-02 The Salk Institute For Biological Studies Treatment of tumorigenic pathophysiological conditions with fgf-cytotoxic conjugates
WO1995003831A1 (en) * 1993-08-02 1995-02-09 Prizm Pharmaceuticals, Inc. Monogenous preparations of cytotoxic conjugates
KR101590495B1 (ko) 2008-05-29 2016-02-01 갤럭시 바이오테크, 엘엘씨 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
CA2800311A1 (en) 2010-05-11 2011-11-17 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
CA2908391A1 (en) 2013-05-01 2014-11-06 Five Prime Therapeutics, Inc. Methods of treating cancer

Also Published As

Publication number Publication date
PL238516B1 (pl) 2021-08-30
EP3468611A1 (en) 2019-04-17
WO2017216620A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
PH12020550240A1 (en) D-domain containing polypeptides and uses thereof
EP4614155A3 (en) Methods of assaying proteins
PE20181923A1 (es) Neoantigenos y metodos de su uso
GB2569252A (en) Methods of combining the detection of biomolecules into a single assay using fluorescent in situ sequencing
MX2018013762A (es) Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso.
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
PE20170665A1 (es) Anticuerpos anti-tau humanizados
MY206284A (en) Anti-cd63 antibodies, conjugates, and uses thereof
MX2022008013A (es) Estabilizacion de polipeptidos que contienen fragmentos cristalizables.
MY187827A (en) New polypeptide having affinity to pd-l1
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
MX2020003260A (es) Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
MX2017006866A (es) Pares de unión para producción de péptidos.
MX2017000083A (es) Compuestos de platino, composiciones y usos de estos.
SG10201903142RA (en) Serpin fusion polypeptides and methods of use thereof
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
SG11201907866SA (en) Horseshoe crab factor b variant
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
TW201613981A (en) Compositions and methods for the diagnosis of rheumatoid arthritis
MX2016010623A (es) Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo.
WO2014160273A3 (en) Protein standard